Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Table 6
Univariate and multivariate analysis of predicting factors for time to CRPC in LVD.
Factors
Univariate hazard ratio (95% CI)
value
Multivariate hazard ratio (95% CI)
value
Age
<75
1 (reference)
≥75
0.94 (0.67–1.30)
0.699
—
Gleason grade group
<4
1 (reference)
≥4
1.82 (1.13–2.96)
0.015
—
Initial PSA level, ng/ml
<100
1 (reference)
≥100
1.03 (0.71–1.51)
0.864
—
TTN, month
<12
1 (reference)
1 (reference)
≥12
0.25 (0.18–0.36)
<0.0001
0.31 (0.05–2.01)
0.222
Nadir PSA level, ng/ml
<0.2
1 (reference)
1 (reference)
≥0.2
5.61 (3.62–8.69)
<0.0001
2.09 (0.88–4.94)
0.094
3-mon PSARR, %
<97
≥97
1 (reference)
1.49(0.98–2.26)
0.063
PSARR, % (month)
<8
1 (reference)
1 (reference)
≥8
4.20 (2.79–6.35)
<0.0001
0.79 (0.13–4.86)
0.802
TFNTC, month
<8
1 (reference)
1 (reference)
≥8
0.18 (0.12–0.26)
<0.0001
0.97 (0.38–2.46)
0.944
PSADT, month
<4
1 (reference)
1 (reference)
≥4
0.45 (0.30–0.68)
<0.0001
0.31 (0.16–0.61)
0.001
TTN: time to PSA nadir, 3-mon PSARR: posttreatment 3 months’ PSA reduction rate, PSARR: PSA reduction rate, TFNTC: time from PSA nadir to CRPC, and PSADT: PSA doubling time.
